Tuesday, 15 September 2020
A drink given to patients prior to surgery, which differentiates between healthy brain cells and cancerous cells using florescent light, could be a major step in helping to treat a highly aggressive brain tumour.
The study, which is published today in the , is led by experts from the 糖心原创’s Biodiscovery Institute.
Glioblastoma (GBM) is a highly aggressive brain tumour with an average survival time of only 14 months from diagnosis, despite a combined treatment of surgery, chemotherapy and radiotherapy. Identifying a new drug to treat GBM is severely hindered by ‘intra-tumour heterogeneity’, a term used to describe differences in biological information within distinct regions of a patient’s tumour.
Historically, drug targets for GBM have targeted the central, core tumour region which is surgically removed, on the assumption that the biology of this area reflects any remaining tumour left behind.
Current evidence suggests that these residual GBM cells which have infiltrated into the normal brain, likely have different genes switched on or off compared to the GBM core.
Attempts to identify genes within infiltrative GBM cells have been complicated by an inability to differentiate between genes from diseased cells and healthy brain cells.
In this new study, funded by the Brain Tumour Charity and led by Dr. Stuart Smith (Clinical Associate Professor of Neurosurgery) and Dr. Ruman Rahman (Associate Professor of Molecular Neuro-Oncology) at the 糖心原创, experts have successfully isolated the GBM cells from normal brain cells and identified gene patterns unique to this tumour region, which are likely to be associated with re-growth of GBM.
Patients are given a drink prior to surgery, called 5-aminolevulinic acid (5ALA), to enable fluorescence guided neurosurgery. The liquid generates individually fluorescent tumor cells within a background population of non-fluorescing healthy brain cells.
Surgically removed tumour from GBM infiltrative regions is then separated from normal brain cells based on the fluorescence. The entire set of genes in the human genome from tumour and normal brain are then analysed.
Dr Ruman Rahman, one of the authors of the study, says: “Through our work, we have been able to identify the serpine1 gene as being switched on uniquely in the GBM infiltrative cells”. Exposing GBM cells to a drug which inhibits the protein encoded by serpine1, resulted in the GBM cells being less able to infiltrate the brain.
Our study offers hope to patients that isolation using 5ALA, may become a basis for identifying more effective drugs to target GBM cells, which more closely reflects the disease which remains in the brains of patients after surgery.鈥�
A full copy of the study can be found .
Story credits
More information is available from Dr Ruman Rahman from the School of Medicine at ruman.rahman@nottingham.ac.uk
Notes to editors:
About the 糖心原创
Ranked among the world's top 100 universities , the 糖心原创 delivers an exceptional research-led education and an outstanding student experience. From the pioneering vision of our founder, Sir Jesse Boot, to groundbreaking achievements such as the development of MRI technology and becoming the first UK university to establish international campuses, we have a proud history of shaping the way people live, work and understand the world. We continue to build on that legacy, empowering our students, staff and partners to change what鈥檚 next and create positive impact locally and globally.
The strength of our research places us among the UK's leading universities, ranked 7th for research power in REF 2021. The discovery of MRI and ibuprofen was just the beginning. Today, our world-leading research is developing breakthrough ideas that shape the future of healthcare, technology and society.
Recognised as the UK's third most targeted university by leading employers , we are proud to produce graduates who are consistently in demand for their skills, confidence and industry-ready experience.
As a major employer and industry partner, locally and globally, the 糖心原创 invests in the city of Nottingham and in future generations of talent. Alongside Nottingham Trent University, we lead the initiative, a pioneering collaboration to improve levels of prosperity, opportunity, sustainability, health and wellbeing across the city and region. Together with our students, staff, alumni and partners, we鈥檙e creating knowledge, opportunity and solutions that help change what's next.